Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21756599 | 1.00 | HPGD (0.53) | HPGDALDH1A1SLC6A2MEN1POLB | |
| SCHEMBL14414850 | 1.00 | HPGD (0.53) | HPGDALDH1A1SLC6A2MEN1POLB | |
| SCHEMBL14414818 | 1.00 | HPGD (0.53) | HPGDALDH1A1SLC6A2MEN1POLB | |
| SCHEMBL5470533 | 1.00 | HPGD (0.53) | HPGDALDH1A1SLC6A2MEN1POLB | |
| SCHEMBL1130657 | 0.87 | ALDH1A1 (0.60) | HPGDALDH1A1POLBTACR2 | |
| SCHEMBL19588714 | 0.87 | ALDH1A1 (0.60) | HPGDALDH1A1POLBTACR2 | |
| SCHEMBL2623390 | 0.87 | ALDH1A1 (0.60) | HPGDALDH1A1POLBTACR2 | |
| SCHEMBL10819414 | 0.87 | ALDH1A1 (0.60) | HPGDALDH1A1POLBTACR2 | |
| SCHEMBL2614786 | 0.87 | ALDH1A1 (0.60) | HPGDALDH1A1POLBTACR2 | |
| SCHEMBL24681013 | 0.86 | ALDH1A1 (0.47) | HPGDALDH1A1SLC6A2TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3873484-B1 | NOVEL STING AGONISTS | VENENUM BIODESIGN LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3873484-B1 | NOVEL STING AGONISTS | VENENUM BIODESIGN LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220048936-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200131209-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC | 2020-04-30 | — | — | US | disclosed |
| US-20200131209-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC | 2020-04-30 | — | — | US | disclosed |
| US-20070225246-A1 | O-acetyl-ADP-ribose non-hydrolyzable analogs | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-27 | — | — | US | disclosed |
| US-6120997-A | LIBRARY OF COMPOUNDS WHICH INHIBIT PROTEIN SYNTHESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2000-09-19 | — | — | US | disclosed |
| EP-0394893-B1 | Purinyl and pyrimidinyl tetrahydrofurans | SQUIBB & SONS INC (US) | 1994-06-29 | — | — | EP | disclosed |
| US-5145960-A | Viricides | E. R. SQUIBB & SONS, INC. (US) | 1992-09-08 | — | — | US | disclosed |
| US-5059690-A | Viricides | E. R. SQUIBB & SONS, INC. (US) | 1991-10-22 | — | — | US | disclosed |
| EP-0394893-A2 | Purinyl and pyrimidinyl tetrahydrofurans | E.R. SQUIBB & SONS, INC. (US) | 1990-10-31 | — | — | EP | disclosed |
| EP-0391411-A2 | 3'-Substituted methyl nucleosides as antiviral agents | Bristol-Myers Squibb Company (US) | 1990-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225246-A1 | O-acetyl-ADP-ribose non-hydrolyzable analogs | PARP1, TIPARP, CD38 | HPGD 231/4885ALDH1A1 1110/4885SLC6A2 4832/4885 |
| US-20200131209-A1 | NOVEL STING AGONISTS | STING1, CGAS, TBK1 | HPGD 3904/4885ALDH1A1 4836/4885SLC6A2 1814/4885 |
| US-11161864-B2 | Sting agonists | STING1, IRF3, CGAS | HPGD 3917/4885ALDH1A1 4840/4885SLC6A2 1553/4885 |
| US-20220048936-A1 | NOVEL STING AGONISTS | STING1, IRF3, CGAS | HPGD 3887/4885ALDH1A1 4812/4885SLC6A2 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.